Zanidatamab: A New Horizon in Treating HER2-Positive/HR-Positive Metastatic Breast Cancer

Scheduled for:Jan 30, 2024 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist or researcher specializing in breast cancer, with a deep understanding of HER2-positive/HR-positive metastatic breast cancer. The expert should have knowledge of current treatment standards and novel therapies, including bispecific antibodies and their role in cancer treatment.

Interview Goal

This interview aims to delve into the recent breakthroughs from the Phase 2a trial of zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib and fulvestrant, presented at the 2023 San Antonio Breast Cancer Symposium. We will examine the trial's efficacy, safety, and potential implications for the treatment of HER2-positive/HR-positive metastatic breast cancer (mBC), focusing on its role as a potential chemotherapy-free option for heavily pretreated patients.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.